$ACA

Arcosa Stockholders Approve Acquisition by CRH

Arcosa (ACA) stockholders approved the acquisition by CRH (CRH) for $150 per share. The deal, expected to close in Q1 2027, is subject to regulatory approvals. Arcosa is an infrastructure products and solutions provider with segments in Construction Products and Engineered Structures.

Original reporting
Published Sep 7, 2026, 2:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 7, 2026, 5:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$ACA
Bullish
high confidence
Mentioned
$ACA · $CRH
Relevance
8/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ACABullishHigh
01

Why it matters

The approval removes a key hurdle, allowing the transaction to proceed toward a Q1 2027 close.

02

Market read

The announcement is a primary M&A disclosure that can drive immediate trading decisions on both tickers.

03

What to watch

Regulatory approvals and financing costs may delay closing.

Relevance 8/10Novelty 8/10Timing: immediate post‑approval

Background

Arcosa, a Dallas‑based provider of construction products and engineered structures, entered a merger agreement with CRH earlier this year.

Company-level read

Ticker impact

$ACABullishHigh confidence
Context

Arcosa stockholders approved the CRH acquisition at a special meeting on September 4, 2026.

Expected impact

Potential upside as the acquisition premium is locked in; price may rise toward the $150 offer level.

Evidence & confidence

Approval confirms deal terms; market will price in the cash offer.

$CRHBullishMedium confidence
Context

CRH is the acquiring party in the all‑cash $150‑per‑share transaction for Arcosa.

Expected impact

CRH stock may experience modest pressure due to cash outlay but could be supported by long‑term synergies.

Evidence & confidence

Acquisition adds scale; short‑term financing impact balanced by strategic fit.

Market effects

Consolidation in the infrastructure products sector may pressure peers.

U.S. construction materials market sees potential re‑rating.

Deal highlights continued M&A activity in global infrastructure space.

Counterpoint

Deal could be over‑priced if integration challenges arise.

Key entities

  • Arcosa, Inc.

    Target of the acquisition.

  • CRH plc

    Acquirer.

Related articles

$IONQMed

Global Competition Law Update for September 2026

Courts denied motions to dismiss in shale oil and HP ink cartridge antitrust cases. Iowa and Montana sued to block states from opposing Paramount Skydance's Warner Brothers Discovery acquisition. FTC allowed IonQ's acquisition of SkyWater to proceed without remedies. DOJ required divestitures in a Tennessee asphalt market deal. In Mexico, the CNA and CONCANACO SERVYTUR discussed competition policy compliance.

$CRHMed

CRH stock hits 52-week low at 86.83 USD

CRH stock hit a 52-week low of $86.83, down 34% from its high. Management has been buying back shares, and analysts see attractive valuation with P/E 15.61 and PEG 0.82. CRH plans to acquire Arcosa for $150 per share, expected to close in Q1 2027. Morgan Stanley and DA Davidson rated CRH overweight/buy with targets of $139 and $137, respectively.

$ACALowAI 8/10

ACA Looks 46.2% Overvalued on GF Value™ Amid CRH Acquisition App

Arcosa Inc (ACA) shareholders approved its acquisition by CRH for $150 per share, pending regulatory approval. ACA's stock is 46.2% overvalued per GF Value™ at $145.45 vs. intrinsic value of $99.52. CRH's acquisition is expected to close in Q1 2027. ACA's GF Score™ is 76/100, with strong momentum and profitability but weak valuation. 9 gurus hold ACA, with 8 adding positions.